Moleculin Biotech, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Moleculin Biotech, Inc. (MBRX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $0 for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2021-11-10
- Moleculin Biotech, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2021-09-30 was $0.00.
- Moleculin Biotech, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2021-06-30 was $0.00.
- Moleculin Biotech, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2021-03-31 was $0.00.
- Moleculin Biotech, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2020-12-31 was $0.00.
- Moleculin Biotech, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Moleculin Biotech, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2019 was $229.00K.
- Moleculin Biotech, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2018 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2021-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2021-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-12 | $0.00 derived: sum of 2 quarters · filed 2021-05-12 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $0.00 10-K · filed 2021-03-24 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | ||||
| 2019-12-31 | $229.00K 10-K · filed 2021-03-24 | ||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-19 | $200.00K 10-K · filed 2019-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |